Opexa begins dosing in trial for multiple sclerosis

The phase IIb clinical study will be designed primarily to evaluate the efficacy, safety and tolerability of the Tovaxin T Cell vaccination with clinically isolated syndrome and relapsing-remitting multiple sclerosis patients. Enrollment is expected to be completed by mid-2007.

All patients who complete the trial will be eligible to participate in an optional one-year extension study, in which they will receive Tovaxin under an open-label protocol. The open-label study is being planned under a different protocol that will be submitted to the FDA.

“We have received a very enthusiastic response regarding the prospects for Tovaxin within the multiple sclerosis community. The screening of patients is proceeding well, and we believe that due to Tovaxin’s excellent safety profile, enrollment will be very attractive to patients and their physicians,” said David McWilliams, president and CEO of Opexa.